The Latest Cardiac and Vascular News
New 220,000 square-foot Distribution Center to support ongoing growth of business PITTSBURGH–(BUSINESS WIRE)–Bayer announced its plans to build a new 220,000 sq. ft. Distribution Center to support the ongoing growth of Bayer’s Radiology global business that supplies medical device products world-wide. A 10-year lease with optional extensions is being negotiated. The facility, which will be […]
Finerenone is a potential first-in-class investigational, non-steroidal, selective mineralocorticoid receptor antagonist (MRA) that works on the pathway of MR overactivation, a key contributor to disease progression in patients with chronic kidney disease and type 2 diabetes FIDELIO-DKD is the first large contemporary positive outcomes study in patients with chronic kidney disease and type 2 diabetes […]
Data presented as a late-breaker during a virtual ALERT session at the annual meeting of the European Respiratory Society Outcomes from the randomized, controlled, open-label REPLACE study included results from 226 patients with pulmonary arterial hypertension (PAH) WHIPPANY, N.J.–(BUSINESS WIRE)–Bayer today announced results from the Phase IV REPLACE (Riociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapy) study, […]
The first and only FDA-approved gadolinium-based contrast agent for multi-patient dosing with an FDA-cleared Transfer Spike in the MR suite. INDIANOLA, Pa.–(BUSINESS WIRE)–Please replace the release with the following corrected version due to multiple revisions. The updated release reads: FDA APPROVES GADAVIST® (GADOBUTROL) IMAGING BULK PACKAGE The first and only FDA-approved gadolinium-based contrast agent for multi-patient […]
WHIPPANY, N.J.–(BUSINESS WIRE)–Lori Moore, former Managing Director at Deloitte, will be joining Bayer as Vice President, Head of Pharmaceutical Communications in the United States, the company announced today. Moore spent the last six years in senior communications roles at Deloitte, most recently as the Managing Director leading efforts to transform internal communications. Prior to joining […]
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain. Sensyne Health Signs Collaboration Agreement with Bayer […]
WHIPPANY, N.J., July 15, 2019 /PRNewswire/ — Bayer announced today the U.S. Food and Drug Administration (FDA) has approved Gadavist® (gadobutrol) injection for use in cardiac magnetic resonance (MR) imaging to assess myocardial perfusion (stress, rest) and late gadolinium enhancement in adult patients with known or suspected coronary artery disease (CAD). Gadavist is now the first and only […]
NETANYA, Israel, May 28, 2019 /PRNewswire/ — Sensible Medical Innovations and Bayer successfully signed an agreement making Bayer, Sensible’s largest customer in Europe. Bayer will use Sensible ReDS™ technology as an exploratory device-derived biomarker to monitor lung congestion in a clinical trial (ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03901729). The ReDS System is a wearable vest which quantifies the amount of lung fluid non-invasively. It can […]
CAMBRIDGE, Mass., June, 29, 2018 /PRNewswire/ — The Broad Institute of MIT and Harvard and Bayer are launching the Precision Cardiology Laboratory (PCL), a new endeavor that will pursue scientific insights aimed at developing new therapies for heart failure. According to the American Heart Association, more than 900,000 people are diagnosed with heart failure every year in the United States. The […]
Bleeding rates were low, and while major bleeding was increased, notably, there was no significant increase in intracranial or fatal bleeding1. This combination regimen demonstrated a substantial improvement in net clinical benefit of 20%1. Data from Canadian-led COMPASS study, revealed at ESC Congress 2017, included 27,395 patients globally and 50 trial sites in Canada. The […]
